Vector BioPharma

Vector BioPharma is a technology company.

Active

Updated: Mar 20, 2026 ·

About

Vector BioPharma AG develops a precision gene delivery platform utilizing engineered virus-like particles to enhance the safety, efficacy, and specificity of genetic medicines. The company's innovative technology delivers significantly larger genetic payloads, up to 36 kb, surpassing the capacity of conventional viral vectors. This platform also features proprietary capsid shielding and specific adapter proteins, enabling precise cell and tissue targeting while minimizing immunogenic responses through its gene-devoid nature. The approach allows for tunable expression of multiple genes, aiming to address critical challenges in current gene therapy.

The company was formally launched on August 10, 2022, by Versant Ventures, stemming from its Ridgeline Discovery Engine in Basel, Switzerland. The foundational technology originated from the laboratory of Andreas Plückthun, Ph.D., a professor of protein engineering at the University of Zürich, who pioneered the engineered virus-like particle. Lorenz Mayr, Ph.D., serves as CEO, bringing extensive biopharmaceutical executive experience to lead the company's development.

Vector BioPharma focuses on improving treatments for patients by transforming drug delivery. The company envisions its platform advancing genetic medicine, with early applications targeted towards immuno-oncology and genome editing. Their long-term vision centers on fundamentally improving patient outcomes through enhanced delivery of biologics, cell, and gene therapies.

Recent News & Mentions

Aug 1, 2022FundingVector BioPharma - Series A

Financial History

Vector BioPharma has raised $30.0M across 1 funding round. Most recently, it raised $30.0M Series A in August 2022.

Total Raised

$30.0M

Valuation

N/A

Funding Rounds Raised

Date	Round	Lead Investors	Other Investors
Aug 1, 2022	$30.0M Series A		Versant Ventures

Financial History

Vector BioPharma has raised $30.0M across 1 funding round.

Total Raised

$30.0M

Valuation

N/A

Deep Dive

High-Level Overview

Vector BioPharma AG is a Basel, Switzerland-based biopharmaceutical company developing a precision gene delivery platform using engineered adenoviral vectors devoid of viral genes.[1][2][3] The platform addresses key challenges in gene therapy—tissue-specific delivery, large genetic cargo capacity, and reduced immunogenic reactions—enabling safer, more efficacious biologics, cell, and gene therapies for areas like immuno-oncology and genome editing.[1][2][3] Launched in 2022 with a $30 million Series A from Versant Ventures, it serves patients needing advanced genetic treatments, with a 40-45 person team (mostly PhD scientists) planning proof-of-concept data in 2023 and pipeline expansion.[1][2][3]

Origin Story

Vector BioPharma emerged from over a decade of research by Andreas Plückthun, a University of Zurich professor and pioneer in protein engineering with 500+ publications.[1][2][3] In 2021, Plückthun partnered with Versant Ventures and Lorenz Mayr, Ph.D., a biopharma executive now serving as CEO, to spin out the technology from Plückthun's lab via Versant's Ridgeline Discovery Engine in Basel.[1][3] Versant officially launched the company on August 10, 2022, with a $30 million Series A, building on early work by team members like Sheena Smith, Ph.D., who contributed to platform development as a post-doc.[1][2] Pivotal early traction includes assembling a 40-45 member international team and targeting in vivo data for lead programs by mid-2023.[1][2][3]

Core Differentiators

Vector BioPharma stands out in gene delivery through these key advantages:

Non-viral gene platform: Engineered adenoviral vectors without viral genes bypass immune responses, enabling tunable gene expression without genomic integration.[1][2][3]
Large cargo capacity and precision targeting: Handles unprecedented DNA sizes via proprietary capsid shielding, targeting any cell surface epitope for tissue-specific delivery.[1][2][3]
Overcomes field limitations: Solves payload specificity, cargo size limits, and immunogenicity issues plaguing rivals.[1][2]
Strong scientific foundation: Rooted in Plückthun's protein engineering expertise, with a 70% PhD-level team focused on immuno-oncology and genome editing proof-of-concepts.[2][3]

Role in the Broader Tech Landscape

Vector rides the explosive growth in gene and cell therapies, where precise delivery remains the "grand challenge" amid hundreds of competing firms.[3] Its timing aligns with surging demand for safer vectors post-AAV limitations and CRISPR advances—Versant, a CRISPR Therapeutics founder, sees it as the "new wave" in genetic medicine.[2] Market forces like rising biologic approvals and urgent needs in oncology/genome editing favor its platform, potentially transforming therapies' safety and specificity.[1][5] By licensing tech (e.g., iBET collaboration) and expanding from Basel's biotech hub, Vector influences the ecosystem through innovation spillover and Versant's network.[1][4]

Quick Take & Future Outlook

Vector BioPharma is poised to advance its pipeline with post-2023 in vivo data, likely attracting follow-on funding or partnerships amid gene therapy's momentum.[1][2] Trends like larger-payload editing tools and immune-evading vectors will propel it, potentially evolving from platform developer to multi-program leader influencing precision medicine. As a Versant spinout solving delivery bottlenecks, it could redefine gene therapy accessibility, building on its 2022 launch to deliver transformative patient impact.[1][3]

Sources

Frequently Asked Questions

How much funding has Vector BioPharma raised?

Vector BioPharma has raised $30.0M in total across 1 funding round.

Who are Vector BioPharma's investors?

Vector BioPharma's investors include Versant Ventures.